Repository NIGMS Human Genetic Cell Repository
Subcollection Heritable Diseases
Protocols Protocol PDF
Biopsy Source Skin
Cell Type Stem cell
Tissue Type Induced pluripotent stem cell
Transformant Reprogrammed (Retroviral)
Race Caucasian
Hispanic Ethnicity Not Hispanic/Latino
Country of Origin USA
Family Member 1
Family History N
Relation to Proband proband
Confirmation Karyotypic analysis and Molecular characterization
ISCN 46,XY[25]
Species Homo sapiens
Common Name Human
Remarks Induced pluripotent stem cell; subject affected with sporadic Alzheimer's disease; age last cognitively unimpaired: 77 years (onset at 78 years); history of low blood pressure; hypercholesterolemia, shingles, chest pain; no history of heart attack, cancer, stroke or depression; history of Alzheimer’s onset: changes in short term memory noticed at age of 80 years; functional status at 80 years of age: problems word finding and remembering names, carried out activities independently, worked on the computer, and drove without getting lost; functional status at age 87 years: fully dependent on others, less able to understand spoken words; is less understood and gets upset when others want to help with care tasks (like brushing teeth); gets angry more easily; sleeps long hours despite daytime naps; APOE genotype 3/3 ; test scores at sample collection (age 83 years): cognitive - Blessed IMC 14 of 33 (#errors/33), cognitive - Folstein MMSE 18 of 30 (#correct/30), cognitive - Mattis dementia rating 110 (0-144), functional - A.Q. (IADL) 14 of 30 (higher = more dependent), mood - GDS depression screen 2 (<5 = negative), global - clinical dementia rating of 1 (range 0-3); test scores at age 87 years: cognitive - Blessed IMC 32 of 33 (#errors/33), cognitive - Folstein MMSE 0 of 30 (#correct/30), cognitive - Mattis dementia rating 17 (0-144), functional - A.Q. (IADL) 30 of 30 (higher = more dependent), global - clinical dementia rating of 3 (range 0-3); surgeries include: triple bypass surgery, spinal stenosis surgery; medications include: Namenda, Celexa, Digoxin, Tylenol; Publication: patient sAD2.2 in Nature 482 (7384): 216-220 (PMID 22278060). This iPSC line was submitted by Dr. Lawrence Goldstein (University of California San Diego). GM24666 is a noted slow grower. Please refer to the CofA for specific culture instructions in addition to the Protocol.
Passage Frozen 17
 
Induced Pluripotent Stem Cell The frozen cell line submitted to the Repository was recovered and expanded. The expanded line was evaluated for viability surface antigen expression and alkaline phosphatase activity. Pluripotency was assessed via embryoid body (EB) formation and PluriTest. Steady-state mRNA expression patterns of undifferentiated iPSC and EBs were determined via real-time PCR. Characterization data are included in the Certificate of Analysis.
 
Remark Induced pluripotent stem cell; subject affected with sporadic Alzheimer's disease; age last cognitively unimpaired: 77 years (onset at 78 years); history of low blood pressure; hypercholesterolemia, shingles, chest pain; no history of heart attack, cancer, stroke or depression; history of Alzheimer’s onset: changes in short term memory noticed at age of 80 years; functional status at 80 years of age: problems word finding and remembering names, carried out activities independently, worked on the computer, and drove without getting lost; functional status at age 87 years: fully dependent on others, less able to understand spoken words; is less understood and gets upset when others want to help with care tasks (like brushing teeth); gets angry more easily; sleeps long hours despite daytime naps; APOE genotype 3/3 ; test scores at sample collection (age 83 years): cognitive - Blessed IMC 14 of 33 (#errors/33), cognitive - Folstein MMSE 18 of 30 (#correct/30), cognitive - Mattis dementia rating 110 (0-144), functional - A.Q. (IADL) 14 of 30 (higher = more dependent), mood - GDS depression screen 2 (<5 = negative), global - clinical dementia rating of 1 (range 0-3); test scores at age 87 years: cognitive - Blessed IMC 32 of 33 (#errors/33), cognitive - Folstein MMSE 0 of 30 (#correct/30), cognitive - Mattis dementia rating 17 (0-144), functional - A.Q. (IADL) 30 of 30 (higher = more dependent), global - clinical dementia rating of 3 (range 0-3); surgeries include: triple bypass surgery, spinal stenosis surgery; medications include: Namenda, Celexa, Digoxin, Tylenol; Publication: patient sAD2.2 in Nature 482 (7384): 216-220 (PMID 22278060). This iPSC line was submitted by Dr. Lawrence Goldstein (University of California San Diego). GM24666 is a noted slow grower. Please refer to the CofA for specific culture instructions in addition to the Protocol.
Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS, Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells Nature482:216-20 2011
PubMed ID: 22278060
No data is available
Passage Frozen 17
Temperature 37 C
Percent CO2 5%
Percent O2 AMBIENT
Medium Knockout DMEM
Serum 20% Knock-out Serum Replacement
Substrate Gelatin + Feeder Layer